Schob Stefan, Kläver Monika, Richter Cindy, Scherlach Cordula, Maybaum Jens, Mucha Simone, Schüngel Marie-Sophie, Hoffmann Karl Titus, Quaeschling Ulf
Abteilung für Neuroradiologie, Universitätsklinikum Leipzig, Leipzig, Germany.
Front Neurol. 2020 Sep 23;11:1050. doi: 10.3389/fneur.2020.01050. eCollection 2020.
Flow diversion has profoundly changed the way aneurysms are treated. However, it conventionally requires dual antiplatelet medication and has yet been considered off-label use in the posterior circulation or within peripheral vessels of the anterior circulation. Here, we report our experience with the p48MW/p48MW hydrophilic coating (HPC) in the anterior and posterior circulation. This novel low-profile flow diverter is specifically designed for treatment of small peripheral vessels, and the p48MW HPC has an anti-thrombotic polymer coating, which allows application of a single antiplatelet function medication in conditions that expectably require further surgery. Thirty-two patients were prospectively included. Twenty-six treatments were performed with one flow diverter, four required two overlapping flow diverters, one case demanded three overlapping flow diverters, and in one case, extensive dissecting aneurysm telescoping with eight flow diverters was necessary. Twenty-two complex bifurcation aneurysms were treated. Three months' follow-up was available for 14 patients. Deployment was uneventful in all cases. In four cases, undersizing was unavoidable and resulted in significant shortening of the flow diverter, which demanded implantation of further flow diverters to sufficiently treat the target aneurysm. Three flow diverters required balloon angioplasty for optimal wall approximation. All parent vessels remained patent. Available 3-month follow-up studies showed decreased influx or delayed washout in all aneurysms; none was occluded completely. There were no device-related clinical complications. Implantation of the p48MW/p48MW HPC is safe and effective for treatment of distally located cerebral aneurysms. Considering the reported rates of ischemic complications associated with flow diversion of complex bifurcation aneurysms, the p48MW/p48MW HPC potentially provides increased safety for complex bifurcation aneurysms in the anterior and posterior circulation.
血流导向术已深刻改变了动脉瘤的治疗方式。然而,传统上它需要双联抗血小板药物治疗,并且在椎基底动脉系统或颈内动脉海绵窦段等外周血管病变的治疗中仍被视为超说明书用药。在此,我们报告了我们使用p48MW/p48MW亲水性涂层(HPC)血流导向装置治疗前循环和后循环动脉瘤的经验。这种新型的低轮廓血流导向装置专为治疗外周小血管而设计,p48MW HPC带有抗血栓聚合物涂层,这使得在预期需要进一步手术的情况下可应用单一抗血小板功能药物。前瞻性纳入了32例患者。使用1个血流导向装置进行了26例治疗,4例需要2个重叠的血流导向装置,1例需要3个重叠的血流导向装置,还有1例需要使用8个血流导向装置进行广泛的夹层动脉瘤套叠术。治疗了22例复杂分叉部动脉瘤。14例患者获得了3个月的随访。所有病例的置入过程均顺利。4例中,尺寸过小不可避免,导致血流导向装置明显缩短,这需要植入更多血流导向装置以充分治疗目标动脉瘤。3个血流导向装置需要球囊血管成形术以实现最佳的管壁贴合。所有载瘤血管均保持通畅。现有的3个月随访研究显示,所有动脉瘤的流入减少或洗脱延迟;无一完全闭塞。没有与装置相关的临床并发症。p48MW/p48MW HPC植入术治疗远端脑动脉瘤安全有效。考虑到报道的复杂分叉部动脉瘤血流导向术相关缺血性并发症的发生率,p48MW/p48MW HPC可能为前循环和后循环的复杂分叉部动脉瘤提供更高的安全性。